Grown Rogue International Inc. (CNSX: GRIN)
Health Care · Pharmaceuticals · US
CA$0.66
+3.13% today · +10.0% 1Y
Grown Rogue International Inc. (CNSX: GRIN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $119.80M and employs 204 people.
Over the last twelve months the share price has gained 10.0%, trading between 0.38 and 0.72.
Tweenvest scores Grown Rogue International Inc. across four factors: quality 58/100, value 56/100, growth 100/100. Its strongest factor is growth.
GRIN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $119.80M
- Revenue (TTM)
- $37.70M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -1.04
- 52-week high
- CA$0.72
- 52-week low
- CA$0.38
- Avg volume (3M)
- —
- Shares outstanding
- 249.94M
- Employees
- 204
- Next earnings
- —
About Grown Rogue International Inc.
Grown Rogue International Inc., operating through its various subsidiaries, specializes in the cultivation and distribution of diverse cannabis products across the United States. Its comprehensive product portfolio features an assortment of cannabis flower strains, including popular indica, sativa, and hybrid varieties. Additionally, the company offers edibles, vape cartridges, convenient pre-rolled joints, and concentrated extracts. These goods are marketed to consumers through licensed dispensaries. Grown Rogue International Inc.'s corporate headquarters are situated in Medford, Oregon.
- ISIN
- CA39986R3045
- Listed since
- Nov 28, 2016
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.70 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.02 | -0.74% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.20 | +0.36% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.